•   
  •   

Health & Fitness AstraZeneca says Tagrisso shown to slow lung cancer spreading to brain

21:05  19 september  2020
21:05  19 september  2020 Source:   reuters.com

This man can't see numbers. But his brain can.

  This man can't see numbers. But his brain can. A rare degenerative brain disorder made it impossible for this man to see the numbers 2 through 9."He described it as being the strangest thing he's ever seen," said David Rothlein, a postdoctoral researcher and cognitive scientist at the Veterans Affairs Boston Healthcare System. This man, referred to by his initials RFS, has a rare degenerative brain condition that does not allow him to "see" numbers — on paper, as objects or even those secretly embedded in scenes.

FRANKFURT (Reuters) - AstraZeneca ’s top-selling drug Tagrisso has been shown to slow the spread of a certain type of lung cancer to the brain when diagnosed at an early stage, the British drugmaker said on Saturday. A study with patients diagnosed early enough for the lung tumour to be

FRANKFURT (Reuters) - AstraZeneca ’s top-selling drug Tagrisso has been shown to slow the spread of a certain type of lung cancer to the brain when diagnosed at an early stage, the British drugmaker said on Saturday. A study with patients diagnosed early enough for the lung tumour to be

a close up of a sign: FILE PHOTO: Logo of AstraZeneca is displayed on a screen on the floor at the NYSE in New York © Reuters/Brendan McDermid FILE PHOTO: Logo of AstraZeneca is displayed on a screen on the floor at the NYSE in New York FRANKFURT (Reuters) - AstraZeneca's top-selling drug Tagrisso has been shown to slow the spread of a certain type of lung cancer to the brain when diagnosed at an early stage, the British drugmaker said on Saturday.

A study with patients diagnosed early enough for the lung tumour to be surgically removed, and who have a mutation of the so-called EGFR gene, found that Tagrisso cut the risk of developing brain metastases by 82%.

Is the UK on the Verge of a Cancer Crisis? This Oncologist and Professor Explains Why

  Is the UK on the Verge of a Cancer Crisis? This Oncologist and Professor Explains Why Provided a 'second wave' doesn't hit, Professor Karol Sikora believes the dissipation of coronavirus could lead to an implosion of cancer cases across the country and provide a killing blow to an-already weakened NHSOn March 23rd, a country-wide 'lockdown' was initiated by the UK, a move that saw wide-ranging restrictions on freedom of movement, enforced by law, prohibiting non-essential activities in a bid to help curb the already-rapid spread of the novel coronavirus (COVID-19). Gyms, barbers and non-essential shops closed to fight it. Public transport emptied. People followed the #StayHome rules and clapped for the NHS' unwavering resilience every Thursday.

AstraZeneca 's top-selling drug Tagrisso has been shown to slow the spread of a certain type of lung cancer to the brain when diagnosed at an early stage, the British drugmaker said on Saturday. A study with patients diagnosed early enough for the lung tumour to be surgically removed, and who have a

FRANKFURT (Reuters) - AstraZeneca ’s top-selling drug Tagrisso has been shown to slow the spread of a certain type of lung cancer to the brain when diagnosed at an early stage, the British drugmaker said on Saturday. A study with patients diagnosed early enough for the lung tumour to be

The late-stage Phase III trial results - presented at the virtual European Society for Medical Oncology (ESMO) conference over the weekend - underscore the drug's potential and may encourage a push to diagnose lung cancer earlier for patients to benefit from the drug, Astra said.

According to earlier findings of the same trial known as ADAURA published in May, Tagrisso held back early-stage EGFR mutated lung cancer, potentially adding billions to its sales potential.

Revenue from Tagrisso climbed 43% to $2 billion in the first half of the year, mainly from EGFR-mutated lung cancer diagnosed when it has already spread to other body parts, driving sales growth in oncology.

The EGFR mutation is found in about a quarter of global lung cancer cases, but the rate in Asia can be more than 40%.

The group has been discussing possible approval for a use of the drug in the early disease setting with global regulators. Analysts have predicted additional sales potential for the drug of between $1 billion and $3 billion from the ADAURA trial.

(Reporting by Ludwig Burger; Editing by David Holmes)

Why Are Young Guys Suddenly Getting Colon Cancer? .
What to know about the puzzling trend you don’t want to be part ofMost troubling of all, many of them were coming in with advanced, metastatic disease. One patient, 46-year-old Dan Luers, an Ironman finisher who worked out close to two hours a day, was given a stage IV diagnosis. Every year, Dr. Ng’s concern grew. But the problem didn’t totally hit home until 2017, when a healthy-looking marine showed up in her office. Just 29 years old, “he was the youngest person I’d ever treated for this type of cancer who didn’t have a family history, and the model of perfect health – extremely fit and active and a healthy eater.” But he had stage IV colorectal cancer.

—   Share news in the SOC. Networks
usr: 0
This is interesting!